Search clinical trials for: cetuximab

Total 1016 results

Gruppo Oncologico del Nord-Ovest

Active, not recruiting

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC)

Metastatic Colorectal Cancer

Italy
Pfizer

Completed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

CRC

China
NCIC Clinical Trials Group

Completed

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Colorectal Cancer

Canada
NCIC Clinical Trials Group
Australasian Gastro-Intestinal Trials Group

Completed

Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

Quality of Life | Colorectal Cancer

Canada, Australia
Sun Yat-sen University

Active, not recruiting

Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer (C-CLASSIC)

Colorectal Cancer

China
Hanmi Pharmaceutical Company Limited

Active, not recruiting

HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor | Locally Advanced Solid Tumor

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Colorectal Carcinoma
University of Arizona
National Cancer Institute (NCI)

Completed

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Head and Neck Cancer | Recurrent Head and Neck Squamous Cell Carcinoma | Oropharyngeal Cancer | HNSCC | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma | Stage IVA Nasal Cavity and... and other conditions

United States
Genmab

Terminated

Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer (GEN206)

Colorectal Cancer

Belgium
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer

Anal Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer

Head and Neck Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Colorectal Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer

Lung Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

Head and Neck Cancer | Precancerous Condition

United States
Groupe Oncologie Radiotherapie Tete et Cou
UNICANCER

Active, not recruiting

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)

HNSCC

France
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States, Puerto Rico, South Africa
National Cancer Institute (NCI)

Completed

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB... and other conditions

United States
Heath Skinner

Completed

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Squamous Cell Carcinoma of the Head and Neck Cancer | Previously-Irradiated

United States
Jonsson Comprehensive Cancer Center
Eli Lilly and Company

Terminated

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage IV HPV-Mediated (p16-Positive)... and other conditions

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Eli Lilly and Company; City of Hope National Medical...

Active, not recruiting

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

Thymic Carcinoma | Thymoma | Clinical Masaoka Stage II to IVA

United States
US Oncology Research
Bristol-Myers Squibb; Pfizer

Active, not recruiting

PhII ICb With/Without Erbitux in MBC Pts (CA225200)

Metastatic Breast Cancer

United States
University of Alabama at Birmingham
Eli Lilly and Company

Completed

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Stage IV Non-Small Cell Lung Cancer

United States
University of Wisconsin, Madison
National Institute of Dental and Craniofacial Research (NIDCR); American Cancer...

Completed

Cetuximab in Head and Neck Cancer Patients

Head and Neck Cancer | Squamous Cell Carcinoma

United States
Jeffrey W. Clark, MD
Wyeth is now a wholly owned subsidiary of Pfizer; Dana-Farber Cancer Institute and other collaborators

Completed

Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer

Colorectal Cancer | Colorectal Adenocarcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Terminated

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Recurrent Lung Adenocarcinoma | Stage IV Lung Adenocarcinoma | Recurrent Large Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma | Stage IV Large Cell Lung Carcinoma

United States, Mexico
Innate Pharma
AstraZeneca

Completed

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States, France
University of California, San Diego
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Nasopharynx Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | HNSCC | Hypopharynx Cancer | Cutaneous Squamous Cell Carcinoma | Lip SCC | Sinonasal Carcinoma

United States
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
Shanghai Zhongshan Hospital

Active, not recruiting

Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC

Colorectal Neoplasms

China
National Cancer Institute, Naples
Azienda Ospedaliera G. Rummo

Active, not recruiting

A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (PACER)

Metastatic Colorectal Cancer

Italy
National Cancer Institute, Naples

Active, not recruiting

Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (V-CHANCE)

Squamous Cell Carcinoma of the Head and Neck

Italy
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (PembroRad)

Squamous Cell Carcinoma of the Head and Neck

France
Centre Leon Berard

Completed

Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL)

Head and Neck Cancer | Metastatic Cancer | Advanced Cancer

France
Sun Yat-sen University

Completed

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

China
Bicycle Health

Enrolling by invitation

Novel Induction to Buprenorphine/Naloxone

Opioid Use Disorder | Opioid Dependence | Opioid Use | Opioid Abuse | Opioid Misuse

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Colorectal Neoplasms

Spain, United States, France, Italy, Belgium, Czechia, United Kingdom, Russian Federation
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

Colorectal Cancer | Lung Cancer | Dermatologic Complications | Therapy-related Toxicity

United States
University of Colorado, Denver
Vasgene Therapeutics, Inc

Completed

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Squamous Cell Carcinoma of Head and Neck

United States
RTOG Foundation, Inc.
Bristol-Myers Squibb

Completed

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Eli Lilly and Company

Completed

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Colorectal Cancer | Metastatic Melanoma | Advanced Cancer | Metastatic Non-small Cell Lung Cancer

United States, Japan, Australia, France
Hoffmann-La Roche

Completed

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Breast Cancer | Solid Tumor | Cancer of Head and Neck

Spain, United States, Belgium, Denmark, France, United Kingdom, Canada, Netherlands, Italy
Trans Tasman Radiation Oncology Group

Active, not recruiting

Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPVOropharynx)

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Australia, New Zealand
Hoffmann-La Roche

Completed

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

Belgium, Spain, France, Germany, United States, United Kingdom, Italy, Australia, Poland
Translational Genomics Research Institute
Eli Lilly and Company

Withdrawn

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

Metastatic Colorectal Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Cutaneous Squamous Cell Carcinoma

United States

Search clinical trials for: cetuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations